Compare Heron Therapeutics Inc (HRTX) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs S&P500 ETF — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while S&P500 ETF trades at $777.33 (market cap $819.04B). The key difference: S&P500 ETF is far larger — about 11062.1× Heron Therapeutics Inc's market cap, and S&P500 ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and S&P500 ETF for 205 Days on average.
| HRTX | SPY | |
|---|---|---|
Market Cap | $74.04M | $819.04B |
Volume | 3,668,095 | 30,746,070 |
Sector | Health | — |
52-Week High | $1.49 | $779.14 |
52-Week Low | $0.27 | $631.99 |
Typical Hold Time | 35 Days | 205 Days |
Enterprise Value | $180.78M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
SPY, the SPDR S&P 500 ETF, trades at $777.26, down 0.24% on the day. The technical outlook is bullish, with moving averages strongly supportive and the price above key support at $775. However, oscillators are neutral, and the 6-day RSI at 75.74 suggests potential overbought conditions. A dividend of $1.89 is scheduled for payment on October 30, 2026.
The ETF's outlook remains tied to broader S&P 500 earnings, which are projected to grow 35% in 2026 but slow to 15% in 2027. Key risks include market-wide valuation concerns and potential profit growth deceleration. Investor sentiment is mixed, with some analysts highlighting defensive positioning and seasonal patterns favoring a year-end rally.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
